Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01326702
Title Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lymphoma

Advanced Solid Tumor

multiple myeloma

Therapies

Veliparib

Rituximab

Bendamustine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.